TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02717962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAL-083, Dianhydrogalactitol
Description: The dosing regimen for patients will be VAL-083 (30 mg/m2) administered IV for 3 consecutive days at the beginning of every 21-day cycle. Patients will continue to receive VAL 083, for up to 12, 21-day treatment cycles or until they fulfill one of the criteria for study discontinuation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAL-083, Dianhydrogalactitol
Description: The dosing regimen for patients will be VAL-083 (30 mg/m2) administered IV for 3 consecutive days at the beginning of every 21-day cycle. Patients will continue to receive VAL 083, for up to 12, 21-day treatment cycles or until they fulfill one of the criteria for study discontinuation.
Study: NCT03930108

Intervention type: OTHER
Intervention: SOFA score
Description: Variables of sequential organ failure assessment score, including: P:F ratio; MAP or vasoactive treatment; creatinine or 24-h diuresis; platelet count; serum bilirubin; GCS.
Study: NCT01691092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: All subjects will receive ketamine to induce glutamate release in the brain
Study: NCT04484181

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Embryo culture in time lapse technology (TLT)
Description: In the TLT group, the selection for transfer was based on morphological and kinetic criteria (with the use of an algorithm). Embryos will be cultured and selected for fresh transfer.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Embryo culture in conventional incubator
Description: For the standard incubation group, the selection for transfer will be based on morphological criteria. Embryos will be cultured and selected for fresh transfer.
Study: NCT03899493

Intervention type: OTHER
Intervention: Observation
Description: Patients will be dispositioned to usual obstetric care which may include minimal intervention if spontaneous labor, induction of labor or augmentation of labor as indicated and dictated by the participants obstetrical provider. This study is observational only.

Intervention type: OTHER
Intervention: Observation
Description: Patients will be dispositioned to usual obstetric care which may include minimal intervention if spontaneous labor, induction of labor or augmentation of labor as indicated and dictated by the participants obstetrical provider. This study is observational only.
Study: NCT00760175

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaxigrip (Aventis-Pasteur Canada)
Description: The intramuscular dose (0.5 mL contains 15 micrograms antigen from each strain and the intradermal doses (2 x 0.1 mL)contain 6 micrograms antigen from each strain.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Vaxigrip (Aventis-Pasteur Canada)
Description: The intramuscular dose (0.5 mL contains 15 micrograms antigen from each strain and the intradermal doses (2 x 0.1 mL)contain 6 micrograms antigen from each strain.
Study: NCT02411123

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: IDgenetix Neuropsychiatric Test Panel
Description: The IDgenetix Neuropsychiatric Test Panel is used to make recommendations on the medication therapy that might be impacted by the genetic background of the patient.
Study: NCT00863954

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resonator Device
Description: comparison of different parameter settings of electromagnetic fields using the Resonator Device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resonator Device
Description: comparison of different parameter settings of electromagnetic fields using the Resonator Device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resonator Device
Description: comparison of different parameter settings of electromagnetic fields using the Resonator Device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resonator Device
Description: comparison of different parameter settings of electromagnetic fields using the Resonator Device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resonator Device
Description: comparison of different parameter settings of electromagnetic fields using the Resonator Device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Resonator Device
Description: comparison of different parameter settings of electromagnetic fields using the Resonator Device
Study: NCT00691574

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Melatonin
Description: up to 3 mg, daily, for up to 1 year

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Enviro-light artificial light box
Description: Subjects will sit in front of an artificial, fluorescent light box (10,000 lux) while completing 25-hours of hourly plasma samples. The light lux level will be well below that identified as safe by the FDA.
Study: NCT01507246

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV morphine sulfate
Description: Patients in this group will receive IV morphine sulfate via PCA pump, as needed. The PCA pump will be set up postsurgically as soon as possible and prior to the patient leaving the PACU or immediately upon transfer to the floor if the stay in the PACU is less than one hour.
Study: NCT02760511

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Anthocyanin
Description: Capsules with different anthocyanin content

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Anthocyanin
Description: Capsules with different anthocyanin content

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Anthocyanin
Description: Capsules with different anthocyanin content

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Anthocyanin
Description: Capsules with different anthocyanin content

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Anthocyanin
Description: Capsules with different anthocyanin content

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study: NCT04165980

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation
Description: Transcranial direct current stimulation delivers a low intensity current of up to 4 mA per session through small and circular shaped electrodes applied over the scalp. This induces a weak but focal electrical field that may modify the excitability of the underlying cortical target in a polarity and activity dependent fashion.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation
Description: Transcranial direct current stimulation delivers a low intensity current of up to 4 mA per session through small and circular shaped electrodes applied over the scalp. This induces a weak but focal electrical field that may modify the excitability of the underlying cortical target in a polarity and activity dependent fashion.
Study: NCT04599218

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prostate Biopsy
Description: Standard of care

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MR US Fusion Guided Prostate Biopsy
Description: Trans-rectal ultrasound (TRUS) guided fusion prostate biopsy (Arm 1) or a Transperineal Ultrasound guided fusion prostate biopsy (Arm 2). All patients will under go a standard ultrasound guided biopsy at the time of their targeted (fusion) biopsy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MR/TRUS Fusion Guided Prostate Biopsy
Description: TRUS images are overlaid on a previously obtained prostate MRI, combined with an electromagnetic tracking system. The urologist then performs directed prostate biopsies at MR-identified targets in addition to the standard prostate biopsies.
Study: NCT03343574

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abdominal Strengthening Exercise
Description: Abdominal strengthening exercises involve the muscles of the abdomen. These exercises are to be done in different positions like lying down (recumbent) position, sitting and standing positions. The person performing the exercise contracts the abdominal muscles for a predetermined number of times (up to 10 times), holds the contracted position for up to 10 seconds and then releases the contraction to relax and return to the original state. These exercises are done for three times everyday.
Study: NCT03712852

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PRF+CAF treated patients
Description: Patients will be treated by coronally advanced flap with addition of PRF membrane

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SCTG+ CAF treated patients
Description: Patients will be treated by coronally advanced flap with addition of SCTG graft

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CAF treated patients
Description: Patients will be treated by coronally advanced flap
Study: NCT03223194

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: AT342
Description: AT342 is an AAV8 vector containing a functional copy of the UGT1A1 gene.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: AT342
Description: AT342 is an AAV8 vector containing a functional copy of the UGT1A1 gene.

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: AT342
Description: AT342 is an AAV8 vector containing a functional copy of the UGT1A1 gene.
Study: NCT03235414

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI
Description: Will receive a one time research MRI (MR elastography)
Study: NCT01507246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXPAREL (bupivacaine liposome injectable suspension)
Description: Patients in this group will receive 266 mg EXPAREL diluted with preservative free 0.9% normal saline to a total volume of 30 cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, an IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.~All patients will be offered rescue analgesia, as needed.
Study: NCT03867253

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ORY-2001 Low dose
Description: 0.6mg ORY-2001 capsule

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ORY-2001 High dose
Description: 1.2mg ORY-2001 capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsule
Study: NCT03235414

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood draw
Description: Will receive a one time blood draw to confirm healthy liver status
Study: NCT00133354

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arimidex (Anastrozole)
Description: Subjects will be randomized in a 1:1 ratio to be given either Arimidex 1 mg or placebo orally. Subjects will receive trial treatment for 36 months while continued on GH.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will be randomized in a 1:1 ratio to be given either Arimidex 1 mg or placebo orally. Subjects will receive trial treatment for 36 months while continued on GH.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Growth Hormone
Description: GH (Nutropin®, Genentech, So. San Francisco, CA) will be administered throughout the trial at a dose of \~0.3mg/kg.w (no more than 0.4mg/kg.w) given subcutaneously (SC) at bedtime daily. Dose adjustments on the GH dose will be made by the investigator at least every 6mo.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Growth Hormone
Description: GH (Nutropin®, Genentech, So. San Francisco, CA) will be administered throughout the trial at a dose of \~0.3mg/kg.w (no more than 0.4mg/kg.w) given subcutaneously (SC) at bedtime daily. Dose adjustments on the GH dose will be made by the investigator at least every 6mo.
Study: NCT04893031

Intervention type: DRUG
Intervention: Tocilizumab
Description: 400mg or 800 mg IV tocilizumab treatment according to patient clinical severity
Study: NCT02866448

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle control
Description: Described in arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoquercetin
Description: Described in arm

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Described in arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isoquercetin plus Aspirin
Description: Described in arm
Study: NCT01453647

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guided Imagery
Description: The intervention consists of three audio-recorded guided imagery scripts formatted as three separate tracks on one CD. Each track is 30 minutes in length and is to be used in a recommended order for the first 6 weeks of the intervention and then used in any order for the follow-up weeks, 7 through 10. Project participants will be instructed to use each CD track, as prescribed, a minimum of once daily. CD Track 1 is a basic relaxation entrainment script; CD track 2 is a pleasant scene imagery script; CD track 3 is a well body imagery script.
Study: NCT01716169

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Helicoll
Description: Helicoll Collagen I Wound Dressing

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard of Care Dressings
Description: Standard of Care wound dressings (e.g. Vaseline gauze)
Study: NCT01600781

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: NutriniDrink/Fortini MF unflavoured (1.5kcal/ml)
Description: During the 6-week Intervention period children allocated to group 1 will consume 2 bottles of study product per day (400ml in total).
Study: NCT00971321

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pandemic influenza vaccine GSK2340272A
Description: Two primary intramuscular (IM) injections
Study: NCT01328626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-199
Description: Arm A (Cohorts 1-8) and Arm B (Cohort 1-6): Subjects in dose escalation phase will receive 1 dose of ABT-199, followed by 6 days off drug, followed by continuous once daily dosing with ABT-199. Arm B (Cohorts 7+): Subjects in dose escalation phase will receive continuous once daily dosing with ABT-199. Arm A and Arm B: Subjects in expanded safety cohort will receive continuous once daily dosing with ABT-199.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-199
Description: Arm A (Cohorts 1-8) and Arm B (Cohort 1-6): Subjects in dose escalation phase will receive 1 dose of ABT-199, followed by 6 days off drug, followed by continuous once daily dosing with ABT-199. Arm B (Cohorts 7+): Subjects in dose escalation phase will receive continuous once daily dosing with ABT-199. Arm A and Arm B: Subjects in expanded safety cohort will receive continuous once daily dosing with ABT-199.
Study: NCT01956942

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Micropulse Laser Trabeculoplasty

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Selective Laser Trabeculoplasty
Study: NCT03017261

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TSolution One®
Description: Total knee arthroplasty with the TSolution One® System for the preparation of the femoral and tibial cuts.
Study: NCT02513082

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sono guided nerve block
Description: Sono guided nerve block is effectively and safely performed for pain relief after total knee arthroplasty

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sono guided nerve block
Description: Sono guided nerve block is effectively and safely performed for pain relief after total knee arthroplasty
Study: NCT00456612

Intervention type: PROCEDURE
Group type: OTHER
Intervention: CyberKnife
Description: Radiosurgery to enhancing high grade glioma in 5 fractions with escalating doses.
Study: NCT01160900

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Coronary angioplasty all lesions
Description: treatment by coronary angioplasty and drug eluting stent of all lesions, adjunctive use of prasugrel and bivalirudin
Study: NCT04114370

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-fluciclovine
Description: Prior to beginning PET imaging, 18F-fluciclovine will be administered as an intravenous bolus injection followed by a 10mL saline flush. 18F-fluciclovine will be injected through a cannula (or indwelling catheter) in an antecubital vein or another vein that will provide access. The administration site will be evaluated pre- and post-administration for any reaction. Documentation of administration to a participant will be recorded or as part of the scan upload, including date, prescription number, dose activity (as measured at time of administration), total volume, and start/stop time of administration.
Study: NCT04370600

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: beta hydroxybutyrate (BHB) ester
Description: Ketone supplementation given 3x/day (60mL per dose, or 22g BHB)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: beta hydroxybutyrate (BHB) ester
Description: Ketone supplementation given 3x/day (60mL per dose, or 22g BHB)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Denatonium benzoate + HVMN ketone placebo flavor mix + Stevia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Denatonium benzoate + HVMN ketone placebo flavor mix + Stevia
Study: NCT02619656

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Description: Patients were randomized to insufflation with CO2.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Ambient air insufflation
Description: Patients were randomized to insufflation with ambient air.
Study: NCT01135056

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SIR-Spheres
Description: One time treatment. Dose administered based on tumour volume. Each vial is 3.0GBq.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib tosylate
Description: Oral Tablet, 400mg B.i.d, until progression or unacceptable toxicity develops
Study: NCT00552058

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: certolizumab pegol (CDP870, CZP)
Description: Certolizumab Pegol 400 mg CZP sc injection 2 x 1 mL CZP (200 mg/mL) at Week 0, 2, and 4

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline 0.9% sc injection 2 x 1 mL Placebo at Week 0, 2 and 4
Study: NCT01701648

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laser CO2
Description: Transplantation of autologous melanocytes using amniotic membrane as a substrate. Transplantation of suspension of autologous melanocytes.
Study: NCT00795405

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exposure to sporting events
Description: Exposure to sporting events

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: No exposure to sporting events
Description: No exposure to sporting events
Study: NCT03989570

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transversus abdominis plane block
Description: The TAP block will be performed laterally behind the midaxillary line between the iliac crest and the most inferior extent of the ribs. The plane between the internal oblique and transversus abdominis muscle will be located around the midaxillary line with the probe transverse to the abdomen. Anteriorly,The needle will be passed to come in plane with the ultrasound beam and placed between transversus and internal oblique posterior to the midaxillary line then, the local anesthetic will be injected

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: erector spinae plane block
Description: The ESP block will be performed into a fascial plane between the deep surface of erector spinae muscle and the transverse processes

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control group
Description: placebo
Study: NCT04259242

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SRP
Description: scaling and root planing with ultrasonic scaler and manual instruments
Study: NCT03604627

Intervention type: OTHER
Group type: OTHER
Intervention: Coronal calcium score measurement
Description: A medical interview with clinical examination by a cardiologist for screening cardiovascular risk factors, including smoking, and looking for symptoms of heart disease as part of routine care.~In accordance with routine care, a fasting and fasting blood test will be performed performed on exam day at Bichat Hospital or at another time, close to the patient's home according to his availability. The biological blood test will include the measurement of plasma triglyceride concentrations, total cholesterol and its HDL and LDL fractions, blood glucose, glycated hemoglobin and serum creatinine with estimated glomerular filtration rate according to the CKD-EPI formula. Sample urinalysis will include measurement of creatinine, proteinuria, and microalbuminuria.~An electrocardiogram (ECG) rest, a cardiac ultrasound, a test and respiratory function tests (EFR) will be performed as part of routine care. Coronal calcium score measurement will be performed as part of the research.
Study: NCT01952678

Intervention type: OTHER
Intervention: DaTscan™ - Non-Caucasian Participants
Description: Participants who previously administered DaTscan™ and had undergone SPECT imaging of the brain per local practice at each institution.

Intervention type: OTHER
Intervention: DaTscan™ - Caucasian Participants
Description: Participants who previously administered DaTscan™ and had undergone SPECT imaging of the brain per local practice at each institution.
Study: NCT02636283

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Entresto
Description: Oral pills

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo group
Description: The placebo pills
Study: NCT03149861

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PET/MR-ultrasound guided Fusion biopsy
Description: All focal lesion with PI-RADS \>=3 on MR or with DCFPyL uptake on PET will undergo a focal fusion biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Systemic TRUS guided biopsy
Description: Transrectal ultrasound guided systemic prostate biopsy
Study: NCT03309605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ELX-02
Description: ELX-02 is a synthetic, designer eukaryotic ribosomal specific glycoside (ERSG) optimized as a translational read-through drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo